Form 4: RA Capital Affiliates Report Director Stock Option Grant in ARS Pharmaceuticals

RA Capital Management and its affiliated funds, along with directors Peter Kolchinsky and Rajeev Shah, have reported the grant of 30,000 stock options to Dr. Peter Kolchinsky by ARS Pharmaceuticals, Inc.

Summary

• RA Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah are listed as reporting persons, all holding roles as Director and/or 10% Owner of ARS Pharmaceuticals, Inc. (SPRY).
• On June 25, 2025, Dr. Peter Kolchinsky was granted 30,000 stock options (Right to Buy) for ARS Pharmaceuticals common stock.
• The exercise price for these options is $17.26 per share.
• The options are set to vest in full on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on Dr. Kolchinsky's continuous service.
• The options have an expiration date of June 24, 2035.
• Dr. Kolchinsky holds these options for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II, with any net proceeds from exercise offsetting advisory fees owed by these funds to RA Capital Management.
• All reporting persons, including Dr. Kolchinsky and Mr. Shah, disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment and incentive for a key director affiliated with a major investor, but it's a routine filing without significant new operational or financial news.

Positives

• The grant of stock options to a director affiliated with a significant institutional investor (RA Capital) can signal alignment of interests between management/board and shareholders.
• The long expiration date (June 24, 2035) provides a substantial window for the options to become valuable, indicating a long-term perspective.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• The value of the stock options is dependent on the future stock price performance of ARS Pharmaceuticals, Inc. relative to the exercise price of $17.26.
• Vesting of the options is subject to Dr. Peter Kolchinsky's continuous service to the Issuer, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The document indicates that the granted stock options will vest in full on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to Dr. Peter Kolchinsky's continuous service. The options have a long-term expiration date of June 24, 2035.

Management Comments

• "The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's board of directors, subject to Dr. Peter Kolchinsky's continuous service to the Issuer through the applicable vesting date."
• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund') and RA Capital Nexus Fund II, L.P. (the 'Nexus Fund II'). The general partner of the Adviser is RA Capital Management GP, LLC (the 'Adviser GP'), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members."
• "Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser."

Industry Context

This Form 4 filing details a standard equity compensation event for a director of a publicly traded biotechnology company. Stock option grants are a common mechanism in the biotech and pharmaceutical industries to incentivize long-term performance and align the interests of directors and executives with shareholders.

Comparison to Industry Standards

• The grant of stock options to a director, particularly one affiliated with a significant institutional investor like RA Capital, is a common practice in the biotechnology sector to provide performance incentives and align interests.
• The exercise price of $17.26 and the grant of 30,000 options are specific to ARS Pharmaceuticals and its compensation structure, and would need to be compared against similar-sized biotech companies' director compensation packages to assess their relative generosity or standard nature. No specific comparable companies or projects are mentioned in the filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to Dr. Peter Kolchinsky, a director and managing partner of RA Capital Management, L.P., which is a 10% owner and investment manager for other reporting funds (RA Capital Healthcare Fund, RA Capital Nexus Fund II), constitutes a related party transaction. The filing clarifies that Dr. Kolchinsky holds the option for the benefit of the funds, and any proceeds will offset advisory fees.

Stakeholder Impact

• Shareholders: The option grant aligns the interests of a key director and significant investor with long-term shareholder value, as the options' value is tied to the company's stock performance.
• Employees: No direct impact on employees mentioned in this filing.
• Customers: No direct impact on customers mentioned in this filing.
• Suppliers: No direct impact on suppliers mentioned in this filing.
• Creditors: No direct impact on creditors mentioned in this filing.

Next Steps

• Monitoring the vesting of the 30,000 stock options on or after June 25, 2026.
• Observing any future exercises of these options by Dr. Peter Kolchinsky or the affiliated funds.

Key Dates

Keywords

SEC Form 4, Insider Transaction, Stock Option Grant, Beneficial Ownership, ARS Pharmaceuticals, SPRY, RA Capital Management, Peter Kolchinsky, Director Compensation, Equity Incentive